#USA #Toronto #AI Governance #Life Sciences #Responsible AI

Life Sciences Leaders and AI Governance

In the landscape of life sciences, the integration of artificial intelligence (AI) is being closely monitored as companies strive to establish governance structures to facilitate its deployment. A compelling report from 2026 reveals that 64% of executives in this field are actively implementing or developing AI governance processes. The findings come from a study conducted by ACTO, which included roundtable discussions and surveys targeting senior leaders in pharmaceuticals, biotechnology, and medical devices.

The report highlights the pressing need for trust as a barrier to widespread AI adoption. A staggering 58% of respondents expressed concerns regarding the lack of clear standards for responsible AI practices within the industry. While the desire to leverage AI exists, the path forward is often obstructed by the precarious balance between potential benefits and ethical considerations. Many executives identified regulatory, legal, or compliance hesitations as the main internal barriers, signaling that technology itself is no longer the primary concern.

Defining Responsible AI

Life sciences leaders have emphasized the characteristics of responsible AI, defining it first and foremost as validated (81%), ethical (79%), and safe (75%). This lexicon reflects the industry's commitment to patient safety and regulatory compliance. Notably, despite a high level of personal comfort with AI—69% of executives report feeling at ease with AI technologies—there exists a substantial concern over how AI is implemented within their organizations; 54% express unease about current practices.

Lisa DeMarco, Legal and Operations Director at Arctic Therapeutics, noted that discussions during the roundtables revealed a broad array of insights on AI adoption and oversight, underscoring the urgent requirement for practical guidance tailored to evaluating AI reliability while prioritizing patient safety.

Governance Foundations

Governance emerged as a pivotal theme. Leaders articulated a vision of governance as an ongoing operational framework that extends beyond initial approvals. They stressed the need for designated business leaders, clear escalation procedures, and detailed Standard Operating Procedures (SOPs). Moreover, there remains an unsolved dilemma concerning accountability: who should ultimately be responsible for the actions of an AI agent? Survey responses indicate a division among executives, with 34% believing the end-user should be accountable, followed by legal/compliance (28%), third-party AI providers (22%), and IT departments (16%). A troubling 23% of organizations do not monitor or discuss the use of unauthorized AI agents, raising serious security concerns.

Bridging the Trust Gap

The study suggests that trust will significantly shape the speed of AI deployment in life sciences. The gap between AI adoption and its supervision indicates a critical hurdle. Executives tend to trust AI systems they interact with more than those implemented within their organizations, which may contribute to hesitancy in broader adoption. Executives expressed a desire for improved outcomes to drive trust, with 29% indicating that the enhancement of results and effects is the foremost anticipated benefit of AI.

As companies progress from initial ventures into more complex AI applications, many leaders aim to prioritize manageable tasks before undertaking more intricate integrations. Currently, two-thirds of executives are already involved in AI projects, but attention is gradually shifting toward challenging interconnections between systems and multi-agent coordination. These complexities invite ongoing discussions around reliability and accountability in AI systems.

Introducing the RAIL Score

To foster a common standard, the Responsible AI in Life Sciences (RAIL) score was introduced. It offers a framework to evaluate AI systems across six responsible AI components, including governance, security, human-centered approach, and value creation. Each component receives a rating to guide organizations in navigating regulatory expectations and ensuring evidence-based trust in their AI solutions.

As companies within the life sciences sector move away from questioning the necessity of agentic AI, they are now focused on determining how to deploy systems they can trust at scale. Yet, with no universal norm currently established, executives seek assurance that governance and security mechanisms are robust enough to meet industry demands. The findings from this pivotal report signal that while the readiness to embrace AI is palpable, a concerted effort is necessary to bridge gaps in trust and accountability, ultimately paving the way for responsible and effective AI deployment.

Conclusion

In light of these insights, organizations in the life sciences must prioritize developing effective governance frameworks to assure ethical AI use. Strengthening trust remains crucial, as the success of AI deployment hinges on leadership confidence in the systems they implement, thereby enhancing patient safety and regulatory compliance in the industry.